articleOphthalmologyDec 31, 2008Closed access

Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study

Houston Methodist · Methodist Hospital · +4 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,313
total citations
FWCI
51.45
Percentile
100%
References
13
Citations per year

Authors

6

Topics & keywords

Keywords
  • Verteporfin
  • Medicine
  • Macular degeneration
  • Photodynamic therapy
  • Ranibizumab
  • Ophthalmology
  • Antiangiogenic therapy
  • Optometry
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding